Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Case report: Treatment of parkinsonism secondary to ciltacabtagene autoleucel using a combination dopaminergic regimen

by Manouvakhova, Olga , Goldsmith, Scott R. , Mason, Xenos L. , Aliakbar, Raya , Rosenzweig, Michael , Wong, Cindy , Htut, Myo , Janakiram, Murali , Pulst-Korenberg, Johannes

in Amantadine - administration & dosage / Amantadine - therapeutic use / Antigens / Antiparkinson Agents - administration & dosage / Antiparkinson Agents - adverse effects / Apathy / Basal ganglia / Biological Products - administration & dosage / Biological Products - adverse effects / Biological Products - therapeutic use / CAR-T / Carbidopa - administration & dosage / Central nervous system diseases / ciltacabtagene autoleucel / Cognition / Dopamine / Dopamine Agents - administration & dosage / Dopamine Agents - adverse effects / Dopamine Agonists - administration & dosage / Dopamine Agonists - adverse effects / Dopamine Agonists - therapeutic use / Dopamine receptors / Drug Combinations / Drug Therapy, Combination / Encephalitis / Female / Hemoptysis / Humans / Immunosuppression / Immunotherapy, Adoptive - adverse effects / Immunotherapy, Adoptive - methods / Indoles - administration & dosage / Indoles - adverse effects / Levodopa / Levodopa - administration & dosage / Levodopa - adverse effects / Lymphocytes / Male / Middle Aged / movement and neurocognitive toxicity / Movement disorders / multiple myeloma / Neurotoxicity / Ostomy / Parkinson's disease / Parkinsonian Disorders - chemically induced / Parkinsonian Disorders - drug therapy / parkinsonism / Receptors, Chimeric Antigen - immunology / Sepsis / Staphylococcus infections / Tomography / Treatment Outcome

2024

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Case report: Treatment of parkinsonism secondary to ciltacabtagene autoleucel using a combination dopaminergic regimen

by Manouvakhova, Olga , Goldsmith, Scott R. , Mason, Xenos L. , Aliakbar, Raya , Rosenzweig, Michael , Wong, Cindy , Htut, Myo , Janakiram, Murali , Pulst-Korenberg, Johannes

2024

Confirm

Do you wish to request the book?

Case report: Treatment of parkinsonism secondary to ciltacabtagene autoleucel using a combination dopaminergic regimen

by Manouvakhova, Olga , Goldsmith, Scott R. , Mason, Xenos L. , Aliakbar, Raya , Rosenzweig, Michael , Wong, Cindy , Htut, Myo , Janakiram, Murali , Pulst-Korenberg, Johannes

2024

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Case report: Treatment of parkinsonism secondary to ciltacabtagene autoleucel using a combination dopaminergic regimen

Manouvakhova, Olga,

Goldsmith, Scott R.,

Mason, Xenos L.,

Aliakbar, Raya,

Rosenzweig, Michael,

Wong, Cindy,

Htut, Myo,

Janakiram, Murali,

Pulst-Korenberg, Johannes

2024

Overview

We report on a patient with ciltacabtagene autoleucel-induced movement and neurocognitive toxicity, which was refractory to immunosuppression but responsive to combination dopaminergic therapy (carbidopa/levodopa, ropinirole, amantadine). Response was seen upon both initial treatment and rechallenge after unintended withdrawal. This is the first report of a successful symptomatic treatment of this well-described neurotoxic syndrome.

Share this book

Add to My Shelf

Publisher

Frontiers Media SA,Frontiers Media S.A

Subject

Amantadine - administration & dosage

/ Amantadine - therapeutic use

/ Antigens

/ Antiparkinson Agents - administration & dosage

/ Antiparkinson Agents - adverse effects

/ Apathy

/ Basal ganglia